SCHEMBL7253695

SCHEMBL7253695

COC(=O)c1cnc(Nc2ccc3ncccc3c2)nc1-c1ccc(OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.54
RAB9A P51151 1/20 0.54
SYK P43405 2/20 0.49
CLK1 P49759 4/20 0.49
TNIK Q9UKE5 1/20 0.47
IGF1R P08069 2/20 0.47
ALOX15 P16050 1/20 0.46
HTT P42858 1/20 0.46
KDR P35968 4/20 0.46
CDK1 P06493 2/20 0.46
P2RY14 Q15391 1/20 0.45
CLK4 Q9HAZ1 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.45
MAPK1 P28482 1/20 0.45
MAPK8 P45983 1/20 0.45
CLK2 P49760 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7258386 0.80 KDR (0.58) NPC1RAB9ASYKTNIKIGF1R
SCHEMBL28243562 0.76 NPC1 (0.66) NPC1RAB9ACLK1TNIKIGF1R
SCHEMBL6319822 0.73 IGF1R (0.50) NPC1RAB9ASYKCLK1IGF1R
SCHEMBL7253189 0.73 MAPT (0.44) NPC1RAB9ASYKALOX15HTT
SCHEMBL31054258 0.73 NPC1 (0.77) NPC1RAB9ATNIKP2RY14MEN1
SCHEMBL7253637 0.72 KDR (0.58) NPC1RAB9ASYKTNIKIGF1R
SCHEMBL29120695 0.72 NPC1 (0.61) NPC1RAB9ACLK1TNIKIGF1R
SCHEMBL7258709 0.70 KDR (0.54) NPC1SYKIGF1RKDRCDK1
SCHEMBL21645794 0.70 CGAS (0.54) NPC1RAB9ASYKTNIKIGF1R
SCHEMBL30503668 0.70 NPC1 (0.71) NPC1RAB9ATNIKHTTP2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003030909-A1 2- AND 4-AMINOPYRIMIDINES N-SUBSTTITUDED BY A BICYCLIC RING FOR USE AS KINASE INHIBITORS IN THE TREATMENT OF CANCER BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-17 WO disclosed